by Staff Writers
Copenhagen, Denmark (SPX) Oct 05, 2012
Malaria-drug monitoring over the past 30 years has shown that malaria parasites develop resistance to medicine, and the first signs of resistance to the newest drugs have just been observed.
At the same time, resistance monitoring at the University of Copenhagen shows that the previously efficacious drug chloroquine is once again beginning to work against malaria. In time that will ensure cheaper treatment for the world's poor.
Scientists and healthcare personnel the world over fear that the malaria parasite will develop resistance to the current frontline treatment against malaria, Artemisinin-based Combination Therapies (ACTs).
Therefore, it is especially good news that resistance monitoring at the University of Copenhagen shows that in several African countries, malaria parasites are succumbing to the formerly used drug chloroquine. The results have just been published in the American Journal of Tropical Medicine and Hygiene.
"70% of the malaria parasites we found in Senegal are reacting once again to chloroquine. This is a trend we have also seen in Tanzania and Mozambique, and which other researchers have shown in Malawi.
Our choice of drugs against malaria is limited and related, so when the malaria parasite once again reacts to a substance, it influences several treatment methods," explains Michael Alifrangis, associate professor at the Center for Medical Parasitology at the University of Copenhagen.
He and Magatte Ndiaye, PhD student at Universite Cheikh Anta Diop in Senegal, are keeping an eye on the malaria parasite's sensitivity to drugs by analyzing the parasites' DNA.
Cheaper treatment for the poor in Africa
"Chloroquine costs only 25 US cents for a four-day cure, while the current and corresponding ACTs cost two dollars. Chloroquine was a fantastic malaria drug that lasted for 50 years. However, it was misused for malaria prevention and ordinary fever, and even mixed with cooking salt, so it can come as no surprise that the malaria parasite became resistant to the active ingredient," explains Professor Ib Bygbjerg, M.D. He also points out that reuse will require correct drug use and the training of healthcare personnel to make more accurate diagnoses.
Correct use of drugs paralyzes the development of resistance
"In the near future, chloroquine and other malaria drugs not currently on the market will presumably be able to be used again, if we use them correctly. This means that the drug must be given in combination with other medicine and only to patients who have already developed a certain immunity to malaria and are therefore not at high risk.
At the same time, we must reserve ACTs for the most exposed non-immune groups such as children. Chloroquine is one of the few drugs that can be given to pregnant women at the beginning of their pregnancy," points out Ib Bygbjerg, adding that the patient can be treated with a high dose for a short period, another benefit.
In order to maintain the positive development with chloroquine, it is therefore also important that - with the exception of pregnant women - travellers to malaria areas refrain from taking the drug. Otherwise the parasites will quickly develop resistance once again.
The results have just been published in the American Journal of Tropical Medicine and Hygiene.
University of Copenhagen
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola
Comment on this article via your Facebook, Yahoo, AOL, Hotmail login.
Two people die of cholera in Iraqi Kurdistan
Sulaimaniyah, Iraq (AFP) Oct 2, 2012
Two people have died of cholera in Iraqi Kurdistan's Sulaimaniyah province in the second outbreak in five years, the autonomous region's health minister said on Tuesday. Two elderly people died of the disease last week in Sulaimaniyah, Rekawt Hama Rasheed told AFP, adding that there have been 27 confirmed cases so far. Authorities are testing about 75 people for cholera per day, Rasheed ... read more
|The content herein, unless otherwise known to be public domain, are Copyright 1995-2012 - Space Media Network. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement|